Panitumumab+best supportive care (BSC) significantly improved progression-free survival (PFS) vs BSC alone in patients with chemo-refractory wild-type KRAS metastatic colorectal cancer (mCRC). We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback